You are here

Boosting the innate immune system of the lungs to prevent and treat respiratory v

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43HL118926-01A1
Agency Tracking Number: R43HL118926
Amount: $231,348.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
3900 Essex Lane #250
Houston, TX 77027-5181
United States
DUNS: 786704143
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 BRENTON SCOTT
 (713) 579-9226
 bscott@pulmotect.com
Business Contact
 BRENTON SCOTT
Phone: (713) 579-9226
Email: bscott@pulmotect.com
Research Institution
 Stub
Abstract

7. Project Summary/Abstract Problem: Throughout the world, lower respiratory infections cause significant death and mortality. Seasonal influenza pneumonia alone causes more than 40,000 deaths a year in the U.S. Pandemic influenzas have even more impacts,with at least 50 million influenza-related deaths in 1918-9. Further, the anticipated avian- origin H5N1 influenza in human populations with its associated high mortality is of great concern with no immediate solution currently available. Pulmotect's Solution: Pulmotect has identified and is developing a novel technology to prevent respiratory infections. The lead drug (PUL-042) is a combination of two TLR ligands that stimulates the lung's own innate defense mechanisms to create a hostile environment for pathogens and prevent or attenuate respiratory infections. Both in vitro and in vivo experiments have been completed to validate this technology and the drug is progressing through the regulatory process for a treatment to benefit cancer patients during pe

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government